Latest News and Press Releases

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster...

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig...

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...

Positive CVN424 Phase 2 data for Parkinson’s disease to be presented Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development Novel target, CVN417, for the...

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS)...

Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023 ...

BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig...

CVN766 was well tolerated with no serious adverse eventsCVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolenceData supports once...

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig...